SEC Comment Letter 0000000000-24-005540 to Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc.
Date: May 14, 2024 · CIK: 0001642380 · Accession: 0000000000-24-005540
AI Filing Summary & Sentiment
File numbers found in text: 333-279350
Letter
United States securities and exchange commission logo May 14, 2024 Joshua Riggs President and Chief Executive Officer Oncocyte Corporation 15 Cushing Irvine, CA 92618 Re:Oncocyte Corporation Registration Statement on Form S-3 Filed May 10, 2024 File No. 333-279350 Dear Joshua Riggs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Greg Kramer, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2024
Joshua Riggs
President and Chief Executive Officer
Oncocyte Corporation
15 Cushing
Irvine, CA 92618
Re:Oncocyte Corporation
Registration Statement on Form S-3
Filed May 10, 2024
File No. 333-279350
Dear Joshua Riggs:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Greg Kramer, Esq.